Pds biotech reports an inducement grant under nasdaq listing rule 5635(c)(4)

Florham park, n.j., dec. 23, 2021 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® t-cell activating technology, today announced that the compensation committee of the board of directors of the company approved, on december 20, 2021, an equity award to michael lalond, the company's new director of quality assurance, as a material inducement to mr. lalond entering into employment with pds biotech.
PDSB Ratings Summary
PDSB Quant Ranking